Tomasz Stokłsa

Summary

Affiliation: Medical University of Warsaw
Country: Poland

Publications

  1. ncbi Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor
    T Stokłosa
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
    Apoptosis 9:193-204. 2004
  2. ncbi Prospects for p53-based cancer therapy
    Tomasz Stokłsa
    Department of Immunology, Center for Biostructure, Medical University of Warsaw, Warszawa, Poland
    Acta Biochim Pol 52:321-8. 2005
  3. ncbi Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin
    R Zagozdzon
    Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland
    Int J Cancer 77:720-7. 1998
  4. ncbi The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production
    R Zagozdzon
    Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland
    Cancer Lett 147:67-75. 1999
  5. ncbi Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
    J Gołąb
    Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, Poland
    Life Sci 66:1223-30. 2000

Collaborators

  • C Wojcik
  • J Gołąb
  • S Wilk
  • T Stokłosa
  • R Zagozdzon
  • M Jakobisiak
  • A Giermasz
  • A Jalili
  • P Włodarski
  • P Januszko
  • E Pleban
  • M Marczak
  • G M Wilczynski
  • W Feleszko
  • D Nowicka
  • W Lasek

Detail Information

Publications5

  1. ncbi Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor
    T Stokłosa
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
    Apoptosis 9:193-204. 2004
    ..We demonstrated that in C-26 colon adenocarcionoma higher VEGF production may render endothelial cells susceptible to the proapoptotic activity of PSI and is associated with inhibition of tumor growth...
  2. ncbi Prospects for p53-based cancer therapy
    Tomasz Stokłsa
    Department of Immunology, Center for Biostructure, Medical University of Warsaw, Warszawa, Poland
    Acta Biochim Pol 52:321-8. 2005
    ..Current approaches include several different molecules able to restore p53 wild-type conformation and activity. Such small molecule drugs hold great promise in treating human tumors with dysfunction of p53 pathway in the near future...
  3. ncbi Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin
    R Zagozdzon
    Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland
    Int J Cancer 77:720-7. 1998
    ..Our observations demonstrating potentiation of the antileukemic effects of the IL-12 and doxorubicin combination suggest that the combined use of these 2 agents could be beneficial in leukemia therapy...
  4. ncbi The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production
    R Zagozdzon
    Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Poland
    Cancer Lett 147:67-75. 1999
    ..Therefore, further studies on the possible mechanisms of potentiated antileukemic activity of combination of IL-12 and DOX would be worth pursuing...
  5. ncbi Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice
    J Gołąb
    Department of Immunology, Institute of Biostructure, The Medical University of Warsaw, Poland
    Life Sci 66:1223-30. 2000
    ..As administration of interleukin 12 and indomethacin resulted in enhanced inhibition of angiogenesis it seems possible that prevention of new blood vessel formation is one of the mechanisms responsible for the observed antitumor effects...